Literature DB >> 23067028

Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes.

S Johnston1, S W Janning, G P Haas, K L Wilson, D M Smith, G Reckard, S-P Quan, S Bukofzer.   

Abstract

AIMS: This retrospective administrative claims-based study evaluated comparative persistence and adherence to overactive bladder (OAB) medications in US patients with and without diabetes.
METHODS: Patients ≥ 18 years who initiated OAB medications between 1 January 2005 and 30 June 2008 were analysed from the Truven Health MarketScan Commercial and Medicare Supplemental databases. A 12-month baseline period prior to OAB medication initiation was used to classify patients into diabetes and non-diabetes cohorts, and measure demographic and clinical characteristics. Patients in each cohort were directly matched 1 : 1 based on index year, age, gender and geographic region. Multiple logistic regression was used to compare cohorts on outcomes of ≥ 80% adherence to OAB medications and refilling a second OAB medication prescription. Cox's proportional hazards model compared time to non-persistence with OAB medications between both cohorts.
RESULTS: In total, 36,560 patients were included in each cohort. Compared with the non-diabetes cohort, the diabetes cohort had 21.5% higher odds of ≥ 80% adherence to OAB medications, 16.6% higher odds of filling a second OAB medication prescription and 10.3% lower hazard of non-persistence with OAB medications during a 12-month evaluation period.
CONCLUSIONS: Patients with diabetes were more persistent and adherent to OAB medications and had higher odds of filling a second medication prescription than patients without diabetes. Further research is needed to identify factors responsible for these findings.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23067028     DOI: 10.1111/j.1742-1241.2012.03009.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  8 in total

1.  Factors Influencing Non-Persistence with Antiplatelet Medications in Elderly Patients After Ischaemic Stroke.

Authors:  Martin Wawruch; Dusan Zatko; Gejza Wimmer; Jan Luha; Lenka Kuzelova; Peter Kukumberg; Jan Murin; Adam Hloska; Tomas Tesar; Zoltan Kallay; Rashmi Shah
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

2.  Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS).

Authors:  Kyu Sung Lee; Myung Soo Choo; Ju Tae Seo; Seung June Oh; Hyeong Gon Kim; Kwong Ng; Kyung Jin Lee; Jonathan T Tan; Joon Chul Kim
Journal:  Health Qual Life Outcomes       Date:  2015-06-26       Impact factor: 3.186

Review 3.  Medication adherence in the management of nocturia: challenges and solutions.

Authors:  Ravishankar Jayadevappa; Diane K Newman; Sumedha Chhatre; Alan J Wein
Journal:  Patient Prefer Adherence       Date:  2015-01-13       Impact factor: 2.711

4.  Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.

Authors:  Gillian Yeowell; Philip Smith; Jameel Nazir; Zalmai Hakimi; Emad Siddiqui; Francis Fatoye
Journal:  BMJ Open       Date:  2018-11-21       Impact factor: 2.692

5.  Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.

Authors:  Andrea V Margulis; Marie Linder; Alejandro Arana; Anton Pottegård; Ina Anveden Berglind; Christine L Bui; Nina Sahlertz Kristiansen; Shahram Bahmanyar; Lisa J McQuay; Willem Jan Atsma; Kwame Appenteng; Milbhor D'Silva; Susana Perez-Gutthann; Jesper Hallas
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

6.  Hyposensitivity of C-fiber afferents at the distal extremities as an indicator of early stages diabetic bladder dysfunction in type 2 diabetic women.

Authors:  Wei-Chia Lee; Han-Ching Wu; Kuo-How Huang; Huey-Peir Wu; Hong-Jeng Yu; Chia-Ching Wu
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

Review 7.  Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery.

Authors:  Chun-Hou Liao; Chung-Cheng Wang; Yuan-Hong Jiang
Journal:  Toxins (Basel)       Date:  2016-03-25       Impact factor: 4.546

Review 8.  The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A.

Authors:  Chung-Cheng Wang; Yung-Hong Jiang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2020-03-16       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.